Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two‐year radiographic and clinical outcomes

2002733 citationsJournal Article

Authors

Mark C. Genovese · Stanford University

Joan M. Bathon · Johns Hopkins University

Richard W. Martin · Michigan State University

Roy Fleischmann · Radiant Research (United States)

John Tesser · Center for Clinical Research (United States)

Michael Schiff · Denver Arthritis Clinic

Edward Keystone

Abstract

Etanercept as monotherapy was safe and was superior to MTX in reducing disease activity, arresting structural damage, and decreasing disability over 2 years in patients with early, aggressive RA.

Topics & Keywords

Rheumatoid Arthritis Research and Therapies Lymphoma Diagnosis and Treatment Autoimmune and Inflammatory Disorders Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Arthritis & Rheumatism

Volume 46, Issue 6, pp. 1443-1450

DOI: 10.1002/art.10308

Field-Weighted Citation Impact: 39.15